Orally inhaled nasal drugs
Executive Summary
Chemistry, manufacturing & controls, in vitro and in vivo bioavailability and bioequivalence issues will be discussed April 26 by the Orally Inhaled Nasal Drug Products Subcommittee of the Pharmaceutical Science Advisory Committee to aid the agency in developing draft guidances. The meeting begins at 8.30 a.m. at 5630 Fishers Lane, Rockville, Md